AU2021383599A1 - Respiratory treatments - Google Patents

Respiratory treatments Download PDF

Info

Publication number
AU2021383599A1
AU2021383599A1 AU2021383599A AU2021383599A AU2021383599A1 AU 2021383599 A1 AU2021383599 A1 AU 2021383599A1 AU 2021383599 A AU2021383599 A AU 2021383599A AU 2021383599 A AU2021383599 A AU 2021383599A AU 2021383599 A1 AU2021383599 A1 AU 2021383599A1
Authority
AU
Australia
Prior art keywords
lipopeptide
salt
foregoing
optionally substituted
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021383599A
Other languages
English (en)
Other versions
AU2021383599A9 (en
Inventor
Crawford Linden Alexander CURRIE
Bomi FRAMROZE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2021383599A1 publication Critical patent/AU2021383599A1/en
Publication of AU2021383599A9 publication Critical patent/AU2021383599A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021383599A 2020-11-17 2021-11-15 Respiratory treatments Pending AU2021383599A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114976P 2020-11-17 2020-11-17
US63/114,976 2020-11-17
US202163211972P 2021-06-17 2021-06-17
US63/211,972 2021-06-17
PCT/US2021/059416 WO2022108883A1 (en) 2020-11-17 2021-11-15 Respiratory treatments

Publications (2)

Publication Number Publication Date
AU2021383599A1 true AU2021383599A1 (en) 2023-05-25
AU2021383599A9 AU2021383599A9 (en) 2024-02-08

Family

ID=81709617

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021383599A Pending AU2021383599A1 (en) 2020-11-17 2021-11-15 Respiratory treatments

Country Status (9)

Country Link
US (1) US20240002436A1 (https=)
EP (1) EP4247165A4 (https=)
JP (1) JP2023549855A (https=)
KR (1) KR20230110295A (https=)
AU (1) AU2021383599A1 (https=)
CA (1) CA3199088A1 (https=)
MX (1) MX2023005663A (https=)
TW (1) TW202233647A (https=)
WO (1) WO2022108883A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101524A1 (en) * 2023-11-06 2025-05-15 Hbc Immunology Inc. Lipopeptide compounds, and use in modulating eosinophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
JPH0611754B2 (ja) * 1985-10-09 1994-02-16 サントリー株式会社 ペプチダ−ゼ阻害作用を有する新規化合物及びその製法並びに用途
EP0201743B1 (en) * 1985-04-16 1992-04-01 Suntory Limited Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
KR101250812B1 (ko) * 2011-03-18 2013-04-04 미원상사주식회사 언데세노일 디펩타이드 유도체 및 이를 함유하는 피부미백용 화장료 조성물
US20140154257A1 (en) * 2012-06-07 2014-06-05 Luanne Robalo DeChristopher Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2017068477A1 (en) * 2015-10-18 2017-04-27 Rao M Surya Compound, composition and uses thereof

Also Published As

Publication number Publication date
WO2022108883A1 (en) 2022-05-27
CA3199088A1 (en) 2022-05-27
US20240002436A1 (en) 2024-01-04
KR20230110295A (ko) 2023-07-21
EP4247165A4 (en) 2025-01-22
AU2021383599A9 (en) 2024-02-08
MX2023005663A (es) 2023-05-26
EP4247165A1 (en) 2023-09-27
JP2023549855A (ja) 2023-11-29
TW202233647A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
JP7593577B2 (ja) アミノ酸組成物及びその使用
US6369106B1 (en) Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US8481085B2 (en) Pharmaceutical compositions comprising cannabigerol
US8337815B2 (en) Pulmonary surfactant formulations
US20090149530A1 (en) Antiinfective Flavonol Compounds and Methods of Use Thereof
CN115215914A (zh) 核苷类似物及其用途
TW202017568A (zh) 環絲胺酸化合物的製劑及其應用
US20020107176A1 (en) Brain targeted low molecular weight hydrophobic anti oxidant compounds
WO2011156003A2 (en) Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
CN107614480A (zh) 新型单硫醇粘液溶解剂
RU2528333C2 (ru) Соединения и способы лечения боли и других заболеваний
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
AU2021383599A9 (en) Respiratory treatments
KR101536839B1 (ko) Ａｇｅ 억제제
MX2011013311A (es) Propiedades neuroprotectoras de 5'-metiltioadenosina.
ES3058840T3 (en) Salmonid oil compositions for use in the treatment of eosinophilic related inflammatory and respiratory conditions
JP2011231022A (ja) イミダゾロン誘導体
US12325688B2 (en) Gingerenone A prodrugs as sensotherapeutics and methods of use
RU2396076C1 (ru) Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
WO2025101524A1 (en) Lipopeptide compounds, and use in modulating eosinophilia
JP2008019188A (ja) 新規カルノシン誘導体及び組成物
JP5222608B2 (ja) 抗不安作用剤
WO2025199179A2 (en) Oxytocin peptide analogs
JP3750983B2 (ja) 骨疾患の治療剤
CN115724779A (zh) 酰胺烷二硫化合物、其制备方法和用途

Legal Events

Date Code Title Description
SREP Specification republished